Journal
BRAIN RESEARCH
Volume 1230, Issue -, Pages 273-280Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.brainres.2008.06.124
Keywords
Alzheimer's disease; RAGE; blood-brain barrier; hippocampus; beta-amyloid peptide; microvessels
Categories
Funding
- NIH [R01 AG027910]
- Alzheimer's Association
- Rae and Jerry Richter Fund (at the Neurosurgery Foundation, Brown University, Providence, RI)
- Saunders Family Fund (at the Neurosurgery Foundation, Brown University, Providence, RI)
Ask authors/readers for more resources
Microvascular accumulation and neuronal overproduction of amyloid-beta peptide (A beta) are pathologic features of Alzheimer's disease (AD). In this study, we examined the receptor for advanced glycation endproducts (RAGE), a multi-ligand receptor found in both neurons and cerebral microvascular endothelia that binds A beta. RAGE expression was assessed in aged controls (n=6), patients with early AD-like pathology (n=6), and severe, Braak V-VI AD (n=6). Human hippocampi were stained with a specific polyclonal antibody directed against RAGE (Research Diagnostics, Flanders, NJ). Immunoreactivity was localized in both neurons and cerebral endothelial cells. Quantitative image-analyses were performed on grayscale images to assess the total surface area of endothelial RAGE immunoreaction product in cross sections of cerebral microvessels (5-20 mu m). Confocal images were acquired for confirmation of RAGE immunoreactivity in both microvessels and neurons by coupling RAGE with CD-31 and neurofilament, respectively. A significant increase in endothelial RAGE immunoreactivity was found in severe Braak V-VI AD patients when compared to aged controls (p<0.001), and when compared to patients with early AD pathology (p=0.0125). In addition, a significant increase in endothelial RAGE immunoreactivity was witnessed when comparing aged controls having no reported AD pathology with patients having early AD-like pathology (p=0.038). Our data suggest that microvascular RAGE levels increase in conjunction with the onset of AD, and continue to increase linearly as a function of AD pathologic severity (p<0.0001). (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available